SB-01 is under clinical development by SynCore Biotechnology and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect SB-01’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 19 Aug 2021, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their SB-01 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

SB-01 overview

SB-01 (SCB01A, DBPR104) is under development for the treatment of solid tumour and cholangiocarcinoma. The drug candidate is a new chemical entity with anti-cancer activity and is administered by intravenous route. It is a heterocyclic combretastatin A-4 (CA-4) analogue. The drug candidate acts by targeting tubulin. It was also under development for recurrent or metastatic squamous cell carcinoma in head and neck,

SynCore Biotechnology overview

SynCore Biotechnology (SynCore) a subsidiary of Sinphar Pharmaceutical Co Ltd, is a bio pharmaceutical company that new drug by research and development management and integration of technology resources. The company’s pipeline products include SB01, SB02, SB03, SB04 and SB05; and diagnostic device. Its SB01 drug is a new chemical entity (NCE) that is developed for treating solid tumors, head and neck cancer. SynCore provides SB02 for solid tumors; and SB04 for age-related macular degeneration. The company’s SB05 is a composition of cytostatic drug paclitaxel combined with neutral and positive lipids is being developed for breast cancer; and its marketed product SB03 is an ointment developed for the treatment of external genital warts. SynCore partners with other pharmaceutical companies, non-profit foundation and biotechnology company. The company has its operations in I-Lan and Taipei, Taiwan. SynCore is headquartered in Yilan City, Taiwan.

Quick View SB-01 LOA Data

Report Segments
  • Innovator
Drug Name
  • SB-01
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.